|Articles|March 9, 2020
Novotech Wins Contract for Komipharm Coronavirus Covid-19 Trial in South Korea
Advertisement
Asia-Pacific biotech CRO Novotech has been selected for the Komipharm International clinical trial of Panaphix as a potential treatment for coronavirus - Covid-19. Panaphix is a cytokine storm inhibitor that restrains the overproduction of immune cells and their activating compounds, cytokines.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Is Artificial Intelligence Coming for Clinical Research?
2
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
3
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
4
The CRA Role’s Co-evolution With Clinical Trial Technology
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
